FOTIVDA® (tivozanib)
FOTIVDA® (tivozanib) is an oral, once-daily, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1-3
References: 1. FOTIVDA (tivozanib) USPI March 2021. 2. FOTIVDA (tivozanib) SmPC August 2017. 3. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a Phase III trial. J Clin Oncol. 2013;31(30):3791-3799.
Please report any suspected adverse events (AEs) or product complaints for FOTIVDA® (tivozanib) by contacting AVEO Pharmaceuticals, Inc. at 1-833-FOTIVDA (1-833-368-4832). If you prefer, you may contact the FDA to report AEs at 1-800-FDA-1088 or www.fda.gov/medwatch.
See published FOTIVDA data
Explore pivotal data and ongoing clinical trial publications, including overall survival, long-term PFS, and more.
Learn about
AVEO ACE is a comprehensive program dedicated to providing personalized support for patients and their loved ones throughout the FOTIVDA treatment journey.
In development
As part of our goal to help patients with cancer live better lives, we are seeking to advance other candidates with the potential to positively impact treatment.
AVEO aims to leverage its existing collaborations and partnerships, as well as enter into new strategic collaborations and partnerships to continue to advance each of its product candidates.